EMA Authorised: Iclusig (ponatinib) — Incyte Biosciences Distribution B.V.

View source ↗

Summary

The European Medicines Agency authorised Iclusig (ponatinib) from Incyte Biosciences Distribution B.V. for certain leukemias, including chronic myeloid leukemia…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Chronic Myeloid Leukemia

Drugs mentioned

• Iclusig (ponatinib)

Snippet

Status: Authorised. Therapeutic area: Leukemia, Myeloid;Leukemia, Lymphoid. MAH: Incyte Biosciences Distribution B.V.. Decision date: 05/03/2026. Accelerated assessment